GlaxoSmithKline has announced that the European Commission has granted marketing authorisation for Incruse (umeclidinium) powder delivered by the Ellipta inhaler,...
GlaxoSmithKline and Theravance have announced positive results from two Phase III studies, which showed that patients with Chronic Obstructive Pulmonary...
GlaxoSmithKline has announced that the FDA has approved Incruse Ellipta (umeclidinium) as an anticholinergic indicated for the long-term, once-daily, maintenance...
GlaxoSmithKline has announced positive results from two head-to-head studies directly comparing the efficacy and safety of Incruse Ellipta (umeclidinium) to...
GlaxoSmithKline and Innoviva announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI)...
Incruse Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for GSK 573719...
GlaxoSmithKline and Innoviva announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta...